Loading...
•
Nov 24, 2024
Lifecore Biomedical Q2 2025 Earnings Report
Reported revenues of $32.6 million for Q2 Fiscal 2025, signed multiple development agreements with new customers, and strengthened balance sheet with financing raising approximately $24.3 million and favorable restructuring of credit facility with BMO.
Key Takeaways
Lifecore Biomedical reported strong revenues of $32.6 million for the second quarter of fiscal 2025, an 8% increase compared to the prior year. Gross margins improved, and the company signed multiple new project agreements. The balance sheet was strengthened through equity financing and restructuring of the credit facility.
Revenues for the quarter were $32.6 million, an 8% increase year-over-year.
Gross margins improved compared to the first quarter due to increased revenues and favorable sales mix.
Signed two new project agreements with new customers, expanding the early-stage development pipeline.
Successfully completed the installation and qualification of a high-speed, multi-purpose 5-head isolator filler, more than doubling capacity.
Lifecore Biomedical
Lifecore Biomedical
Lifecore Biomedical Revenue by Segment
Revenue by Segment
CDMO Revenue
CapyFin.comHA Manufacturing Revenue
CapyFin.com Forward Guidance
Lifecore Biomedical estimates net loss to be $28.6 million to $26.6 million and Adjusted EBITDA to be $19 million to $21 million for fiscal year 2025.
Positive Outlook
- Expected increase in depreciation and amortization.
- Anticipated stock-based compensation.
- Projected financing fees.
- Estimated reorganization costs.
- Forecasted restructuring costs.
Challenges Ahead
- Estimated net loss due to higher stock-based compensation.
- Increased interest expense.
- Former CFO severance.
- Elevated legal expenses related to civil litigation.
- Change in fair value of debt derivatives.
Revenue & Expenses
Visualization of income flow from segment revenue to net income